Phase 3 Trial to Evaluate the Efficacy and Safety of YYC506.
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Dyslipidemias
- Type
- Interventional
- Phase
- Phase 3
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: A multicenter, Double-blind, Randomized, Active-controlled, Double dummy, Parelle-group comparative.Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)Masking Description: Double-blind.Primary Purpose: Treatment
Participation Requirements
- Age
- Between 17 years and 125 years
- Gender
- Both males and females
Description
Phase 3 study to evaluate the effiacay and safety of YYC506 in patients with complex dyslipidemia where LDL-C is properly controlled but TG and HDL-C levels are not regulated by Atorvastatin alone.
Phase 3 study to evaluate the effiacay and safety of YYC506 in patients with complex dyslipidemia where LDL-C is properly controlled but TG and HDL-C levels are not regulated by Atorvastatin alone.
Tracking Information
- NCT #
- NCT04858308
- Collaborators
- Not Provided
- Investigators
- Study Chair: Hyo-soo Kim, Ph.D Seoul National University Hospital Principal Investigator: Hyo-soo Kim, Ph.D Seoul National University Hospital Principal Investigator: Soo Lim, Ph.D Seoul National University Bundang Hospital
Get Well Soon